Overview

Safety Study for Beta Thalassemia Subjects on PTG-300

Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
Phase:
Phase 2
Details
Lead Sponsor:
Protagonist Therapeutics
Protagonist Therapeutics, Inc.